AB Science (XPAR:AB) FFO


XPAR:AB AB Science XPAR:AB
59 GF Score
Price €0.86
GF Value €1.47
Valuation Possible Value Trap
! 11 Warning Signs
View Full Analysis

What is AB Science FFO?

FFO (Funds from operations) only applies to REITs.

XPAR:AB
59GF Score
AB Science XPAR:AB
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AB Science (XPAR:AB) Overvalued in 2026?

Based on GuruFocus' analysis, AB Science stock appears to be undervalued. The current stock price of €0.86 is trading 41.6% below its estimated GF Value™ of €1.47. GuruFocus considers AB Science to be Possible Value Trap.

Key valuation signals for XPAR:AB:

  • FFO:
  • GF Value™: €1.47 vs. price of €0.86 (41.6% below fair value)
  • GF Score™: 59/100 with 11 warning signs

No single metric tells the full story. See the XPAR:AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AB Science Business Description

Other Exchanges ABSCF:USA0Q77:UKA8D:Germany
Address 3, Avenue George V, Paris, FRA, 75008
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
59GF Score

Get the complete analysis for XPAR:AB

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.86
Price
€1.47
GF Value